MMED

MiniMed Group, Inc. Common Stock
NASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES

Key Statistics

Market Cap
$5.48B
P/E Ratio
EPS
$-1.26
Beta
52W High
$20.88
52W Low
$10.65
50-Day MA
$16.33
200-Day MA
$14.89
Dividend Yield
Profit Margin
-10.70%
Forward P/E
PEG Ratio

About MiniMed Group, Inc. Common Stock

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.

Official WebsiteUSAFY End: April

Fundamentals

Revenue (TTM)$3.10B
Gross Profit (TTM)$1.77B
EBITDA$278.00M
Operating Margin8.36%
Return on Equity-9.13%
Return on Assets1.73%
Revenue/Share (TTM)$12.09
Book Value$12.86
Price-to-Book1.57
Price-to-Sales (TTM)1.77
EV/Revenue1.773
EV/EBITDA92.94
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)15.60%
Shares Outstanding$280.84M
Float$27.45M
% Insiders90.72%
% Institutions13.37%

Historical Volatility

HV 10-Day
49.78%
HV 20-Day
47.52%
HV 30-Day
50.86%
HV 60-Day
57.51%
HV Rank

Volatility is currently contracting

Analyst Ratings

Consensus ($20.83 target)
1
Strong Buy
10
Buy
1
Hold

Latest News

MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor

MiniMed Flex™ with Instinct, made by Abbott, combines discreet design, up to 15 days of sensor wear and proven automation to reduce the work and interruptions of diabetes management NORTHRIDGE, Calif., Aug. 17, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) today announced that the MiniMed Flex™ system is now commercially shipping in the U.S. with the Instinct sensor, made by Abbott.

PRNewsWire8/17/2026Neutral
MiniMed to Announce Its Fiscal Year 2027 First Quarter Financial Results

NORTHRIDGE, Calif., July 20, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that it expects to report financial results on Tuesday, September 1, 2026, for its first quarter of fiscal year 2027, which ends on Friday, July 31, 2026.

PRNewsWire7/20/2026Neutral
MiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors

David Endicott, Chief Executive Officer of Alcon, brings global healthcare leadership and public company experience; Linnea Burman adds MedTech operating depth NORTHRIDGE, Calif., June 29, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that David Endicott and Linnea Burman have joined its Board of Directors, effective today, expanding the Board from nine to 11 members.

PRNewsWire6/29/2026Neutral
MiniMed launches Instinct sensors in Europe giving people with diabetes more sensor choice with the same proven outcomes

MiniMed automated insulin delivery and smart MDI systems can now be paired with Instinct and Instinct Go, made by Abbott, the smallest, longest-wear sensors in the company's portfolio NORTHRIDGE, Calif., June 23, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the commercial launch in Europe of both the MiniMed™ 780G system integrated with the Instinct sensor and the MiniMed Go™ system integrated with the Instinct Go sensor.

PRNewsWire6/23/2026Neutral
MiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.

People with type 1 or insulin-requiring type 2 diabetes in the U.S. can now wear MiniMed's smallest pump, paired with the Simplera Sync™ sensor NORTHRIDGE, Calif., June 17, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), today announced its first commercial launch of the MiniMed Flex™ system in the United States — its first app-controlled pump and the company's smallest insulin pump yet.

PRNewsWire6/17/2026Neutral
MiniMed Group Q4 Earnings Call Highlights

MiniMed Group NASDAQ: MMED reported record fiscal 2026 revenue and outlined a slate of product launches it said will support faster growth in fiscal 2027, as management held the company's first earnings call as a standalone public company following its March IPO.

MarketBeat6/3/2026Neutral
MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management NORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (NASDAQ: MMED), a global leader in diabetes technology, today announced an expanded agreement with Abbott to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems.

PRNewsWire6/3/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MMED and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 8/18/2026